Encephalitis Treatment Guidelines
Introduction to Encephalitis Treatment
- The Infectious Diseases Society of America (IDSA) recommends acyclovir as the treatment of choice for patients with suspected encephalitis when diagnostic testing is difficult or results will be delayed 1
- Acyclovir is strongly recommended as empiric therapy for several important reasons, including that Herpes simplex virus (HSV) is the most common cause of treatable viral encephalitis in industrialized countries 2
Diagnosis and Treatment Initiation
- Early treatment with acyclovir significantly reduces mortality in HSV encephalitis from >70% to 20-30% 2
- Delays in treatment beyond 48 hours after hospital admission are associated with poorer outcomes 2
- The IDSA guidelines explicitly state that acyclovir should be initiated in all patients with suspected encephalitis as soon as possible 1
- Acyclovir should be started within 6 hours of admission if initial CSF and/or imaging findings suggest viral encephalitis, diagnostic results will be delayed, or the patient is very unwell or deteriorating 2
Treatment Regimen
- Standard dosing of acyclovir is 10 mg/kg intravenously every 8 hours in adults and children with normal renal function 1, 2
- The duration of treatment is 14-21 days for confirmed HSV encephalitis 2
- The dose must be reduced in patients with pre-existing renal impairment to avoid crystalluria and neurotoxicity 2
Diagnostic Testing
- When diagnostic testing is difficult, initiate acyclovir empirically while awaiting diagnostic results 1, 2
- Perform CSF PCR when possible, as HSV PCR has high sensitivity/specificity but may be negative early in disease 1
- Consider repeat testing if initial CSF PCR is negative but clinical suspicion remains high, repeat CSF PCR 3-7 days later 1
- Use neuroimaging, as MRI is the most sensitive imaging test, and temporal lobe lesions suggest HSV encephalitis 1, 2
Potential Pitfalls in Treatment
- Delaying treatment while awaiting diagnostic confirmation significantly increases mortality 2
- Stopping acyclovir prematurely based on initial negative PCR results can lead to false negatives early in disease 1
- Inadequate duration of therapy, as treatment should continue for at least 14-21 days in confirmed cases 2
- Failing to monitor renal function, as acyclovir can cause crystalluria and nephropathy in up to 20% of patients after 4 days of IV therapy 2
Special Considerations
- In immunocompromised patients, viral clearance may be harder to achieve, and prolonged treatment may be needed 2
- Consider additional antimicrobial coverage (e.g., for bacterial meningitis) based on clinical presentation 1
- For patients with penicillin/cephalosporin allergies who need additional bacterial coverage, alternative agents should be selected 3